Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, ...
A D.C. drugmaker is fighting the FDA on multiple fronts, from trying protect its intellectual property from generic ...
Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...
Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...
Vanda expects to immediately begin preparing BLA and MAA applications for the U.S. and EU.
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) and AnaptysBio, Inc. (Anaptys) (NASDAQ: ANAB) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab ...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant development program.
Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued stocks in the Biotechnology industry for Monday, February 03, 2025. Let’s ...
Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a ...
5d
Vanda Pharmaceuticals Inc. recently made a significant move by filing a new drug application for Tradipitant. The application, targeted at addressing motion sickness, was publicized through a social ...
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a pharmaceutical company with a market capitalization of $256.56 million and impressive gross profit margins of 93.62%, disclosed through a social media post ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback